The FDA has approved tapinarof cream, 1% for the treatment of atopic dermatitis in adults and pediatric patients over 2 years old. Marketed by Organon as VTAMA, tapinarof cream was initially approved in May 2022 for plaque psoriasis. Results from ADORING studies showed significant improvement in AD symptoms with tapinarof cream compared to vehicle alone. Common adverse reactions include respiratory infections, folliculitis, and headaches. In an extension trial, patients who achieved complete disease clearance had an average treatment-free interval of around 80 days. Tapinarof cream, 1% shows promising results for treating atopic dermatitis.
Source link
FDA Approves Topical Tapinarof for Atopic Dermatitis
